Literature DB >> 1593584

Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis--preliminary results of a longterm study.

A V Shaikov1, A A Maximov, A I Speransky, D J Lovell, E H Giannini, S K Solovyev.   

Abstract

Patients with systemic juvenile rheumatoid arthritis (JRA) are often poorly responsive to existing therapeutic modalities. We evaluated the effectiveness of pulse therapy consisting of methylprednisolone 30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4 g/m2 body surface area on the 3rd day, for 18 patients with definite systemic JRA, who were enrolled in an open trial of 12 months' duration. The children received pulse therapy every 3 months; oral methotrexate 10 mg/m2 was started after the first pulse. A rapid and clinically significant suppression of systemic and articular manifestations was seen in all patients. Significant decreases in laboratory indices of disease activity were also observed. Side effects were minor and reversible. The results of our preliminary trial support the development of a controlled study to evaluate the efficacy of pulse therapy in systemic JRA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593584

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis.

Authors:  T J Lehman
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

Review 2.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 3.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

4.  Can non-fundable trials be conducted anyway? The case for open, randomised, actively controlled trials in rheumatology.

Authors:  E H Giannini
Journal:  Ann Rheum Dis       Date:  1998-03       Impact factor: 19.103

Review 5.  [Methotrexate in the therapy of juvenile idiopathic arthritis].

Authors:  D Holzinger; M Frosch; D Föll
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 6.  Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.

Authors:  William G Ambler; Kabita Nanda; Karen Brandt Onel; Susan Shenoi
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

7.  Efficacy of methylprednisolone pulse therapy in children with rheumatoid arthritis.

Authors:  Yahya Aghighi; Lida Attarod; Maryam Javanmard
Journal:  Clin Rheumatol       Date:  2008-07-05       Impact factor: 2.980

8.  Severe low-titer cold-hemagglutinin disease responsive to steroid pulse therapy.

Authors:  R Nanan; W Scheurlen; M Gerlich; H I Huppertz
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

9.  Systemic arthritis in children: a review of clinical presentation and treatment.

Authors:  R Gurion; T J A Lehman; L N Moorthy
Journal:  Int J Inflam       Date:  2011-12-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.